The higher rates of serious A.Es in the placebo patients shows the story there. EMPEROR-preserve enrolled patients already with NYHA II-IV symptoms, so naturally adverse event rate is high in both treatment and placebo groups. That second quote is why they did a dedicated trial to show SGLT2 effectiveness, it's the same quote in emperor trial itself.
But nonetheless, a massive area of need. Just like HFrEF was and is, each new treatment is added to the regime rather than replace the patients current drug. e.g. all HFrEF patients should be on all of ACE/ARNI, BB, Spiro, SGLT2 together if tolerated.
Here's hoping the story is the same for HFpEF... SLGT2... + iPPS! Fingers crossed.
The Funding Paradigm., page-16
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |